证券之星消息，1月15日化学制药板块较上一交易日下跌1.4%，向日葵领跌。当日上证指数报收于 4112.6，下跌0.33%。深证成指报收于14306.73，上涨0.41%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300452 | 山河药辅 | 16.85 | 20.01% | 41.42万 | | 6.70亿 | | 301075 | 多瑞医药 | 62.71 | 11.48% | 2.65万 | | 1.65 Z | | 688176 | 亚虹医药 | 13.16 | 7.69% | 26.47万 | | 3.45亿 | | 300401 | 化园生物 | 16.52 | 3.57% | 1 50.30万 | | 8.28亿 | | 000739 | 普洛药业 | 18.13 | 3.30% | 27.08万 | | 4.87亿 | | 002923 | 润都股份 | 13.04 | 3.16% | 9.42万 | | 1.23亿 | | ...

自愿披露关于APL-2401完成I期临床试验 首例受试者入组公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688176 证券简称：亚虹医药 公告编号：2026-001 江苏亚虹医药科技股份有限公司 二、该药品研发及其他相关情况 APL-2401为全球同步研发的1类创新药，其国际多中心临床试验设计及申报资料符合国际临床试验技术 标准体系要求，成功纳入国家药监局于2025年9月12日发布的《关于优化创新药临床试验审评审批有关 事项的公告（2025年第86号）》规定的"30日通道"，并以仅22个工作日获得批准，成为全国首批获得此 项新政审批通过的项目之一，具体内容详见公司披露于上海证券交易所网站（www.sse.com.cn）的《江 苏亚虹医药科技股份有限自愿披露关于APL-2401临床试验申请获得国家药品监督管理局批准的公告》 （公告编号：2025-046）。该研究已于近日成功完成I期临床首例受试者给药，自获批后仅15个工作日 即实现首例给药，成为新政下首批临 ...

北京商报讯（记者 丁宁）1月8日晚间，亚虹医药（688176）发布公告称，近日，公司自主研发的APL- 2401 在FGFR2/3驱动的晚期实体瘤患者中开展的I期临床试验完成首例受试者入组。 公告显示，APL-2401是公司自主研发的高选择性成纤维生长因子受体2/3（FGFR2/3）双靶点小分子抑 制剂，有望为晚期实体瘤（例如尿路上皮癌、胆管癌、子宫内膜癌、胃癌、乳腺癌、卵巢癌、非小细胞 肺癌和其他特定实体瘤）患者提供一种新的治疗选择。 ...

Group 1 - Jinli Permanent Magnet expects a net profit of 660 million to 760 million yuan for 2025, representing a year-on-year growth of 127% to 161% [1] - Wens Foodstuffs anticipates a net profit of 5 billion to 5.5 billion yuan for 2025, a decrease of 40.73% to 46.12% compared to the previous year [2] - New Open Source plans to repurchase shares worth 40 million to 50 million yuan, with a maximum repurchase price of 25.77 yuan per share [3] Group 2 - Fosun Pharma's subsidiary has had a drug registration application accepted for a new drug targeting ALK-positive non-small cell lung cancer [4] - Leike Film reported a net profit of -86 million yuan for the first three quarters of 2025, indicating a potential annual loss [5] - Crown Stone Technology's application for a specific issuance of A-shares has been accepted by the Shanghai Stock Exchange [6] Group 3 - Dongxin Technology has completed the business registration change for its subsidiary, Lishuan Technology, and has invested 211 million yuan in it [7] - Tianci Materials has increased its commodity futures hedging business limit from 150 million to 300 million yuan [8] - Gaode Infrared's actual controller has reduced his shareholding by 0.54%, bringing his stake down to 62.95% [9] Group 4 - Tianyong Intelligent expects a net profit of 10 million to 15 million yuan for 2025, marking a turnaround from losses [10][11] - China Merchants Energy anticipates a net profit of 6 billion to 6.6 billion yuan for 2025, an increase of 17% to 29% year-on-year [18] - Guangdong Electric Power A's Huizhou Power Plant's Unit 5 has been put into commercial operation, with an investment of 8.05 billion yuan [19] Group 5 - Jianghuai Automobile reported a 42.24% year-on-year increase in sales volume for December 2025 [25] - China Pharmaceutical's subsidiary has received a drug registration certificate for a new medication [26] - TianNeng Co. plans to use up to 12 billion yuan of its own funds for entrusted wealth management [27] Group 6 - Luoyang Huizhong reported a 10.55% month-on-month decrease in sales revenue from live pigs for December 2025 [28] - Baolidi expects a net profit of 145 million to 152 million yuan for 2025, a year-on-year increase of 27.17% to 33.30% [30] - Changchun High-tech's subsidiary has had a melatonin granule registration application accepted [31] Group 7 - Zhongmin Energy reported a 4.46% year-on-year decrease in cumulative on-grid electricity for 2025 [32] - Huaxin Electronics reported a 7.79% year-on-year decrease in consolidated operating revenue for December 2025 [35] - Xiamen Airport reported a 2.79% year-on-year increase in passenger throughput for December 2025 [36] Group 8 - Baiyun Airport reported a 12.27% year-on-year increase in passenger throughput for December 2025 [37] - Pulaike has received a new veterinary drug registration certificate for a chewable tablet [38] - Yunnan Energy Holdings' subsidiary has reduced its stake to 84% after a capital increase [39] Group 9 - Gansu Energy Chemical's new thermal power project has successfully completed trial operation [41] - Zhenghong Technology reported a significant decrease in sales revenue from live pigs for December 2025 [42] - Huasheng Lithium Battery is planning to issue H-shares for listing on the Hong Kong Stock Exchange [43] Group 10 - Jincheng Mining has signed a mining production contract with an estimated total price of approximately 510 million yuan [44] - Microchip Biotech has received approval for clinical trials of a new drug for pancreatic cancer [45] - Yahon Pharmaceutical has completed the first patient enrollment for a Phase I clinical trial of its drug [46]

证券代码：688176 证券简称：亚虹医药 公告编号：2026-001 二、该药品研发及其他相关情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 近日，江苏亚虹医药科技股份有限公司（以下简称"公司"）自主研发的 APL-2401 在 FGFR2/3 驱动的晚期实体瘤患者中开展的 I 期临床试验（以下简称 "该研究"）完成首例受试者入组。现就相关情况公告如下： 一、药品基本情况 APL-2401 是公司自主研发的高选择性成纤维生长因子受体 2/3（FGFR2/3） 双靶点小分子抑制剂，有望为晚期实体瘤（例如：尿路上皮癌、胆管癌、子宫内 膜癌、胃癌、乳腺癌、卵巢癌、非小细胞肺癌和其他特定实体瘤）患者提供一种 新的治疗选择。 公司通过 TAIDD 平台进行靶点多构象模拟，并以其选择性机制作为苗头化 合物发现和设计为核心，从而优化出最终的临床前候选化合物 APL-2401。 APL-2401 是一款通过非共价结合模式与靶点相结合的高选择性的 FGFR2/3 小分 子抑制剂。相比现阶段 FGFR2 或 FGFR3 ...

格隆汇1月8日丨亚虹医药(688176.SH)公布，公司自主研发的APL-2401在FGFR2/3驱动的晚期实体瘤患 者中开展的I期临床试验（简称"该研究"）完成首例受试者入组。APL-2401是公司自主研发的高选择性 成纤维生长因子受体2/3（FGFR2/3）双靶点小分子抑制剂，有望为晚期实体瘤（例如：尿路上皮癌、 胆管癌、子宫内膜癌、胃癌、乳腺癌、卵巢癌、非小细胞肺癌和其他特定实体瘤）患者提供一种新的治 疗选择。 ...

亚虹医药公告，近日，公司自主研发的APL-2401在FGFR2/3驱动的晚期实体瘤患者中开展的I期临床试 验完成首例受试者入组。APL-2401是公司自主研发的高选择性成纤维生长因子受体2/3（FGFR2/3）双 靶点小分子抑制剂，有望为晚期实体瘤患者提供新的治疗选择。 ...

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of December 28, 2025 [1] Core Insights - The report highlights the intensive policy support for brain-computer interface (BCI) technology development, particularly in the medical field, with several policies already implemented [2] - It emphasizes the significant market opportunity in radiation therapy equipment, particularly the ZAP-X system, which is expected to capture a substantial share of the growing market for non-invasive tumor radiation treatment [3] - The introduction of pathology fee reforms is seen as a breakthrough for the commercialization of AI applications in pathology, allowing for better integration of AI-assisted diagnostics into the pricing structure [5] - The report discusses the trend of Chinese innovative drugs entering international markets, which is expected to reduce domestic competition and provide new valuation anchors for these companies [6] - It also notes the promising developments in oral autoimmune drugs and small nucleic acid drugs, with several companies making significant progress in clinical trials [7][9] Summary by Sections 1. Policy Support for BCI Technology - In July 2025, a joint opinion was issued by multiple government departments to promote BCI industry innovation, with medical health being a core application area [2] - The National Medical Products Administration (NMPA) has prioritized the approval of implantable BCI medical devices, with expected registration certificates to be issued by Q1 2026 [2] 2. Radiation Therapy Equipment Market - The ZAP-X system is designed for precise radiation therapy for brain tumors, with a significant patient population in China, estimated at 1.5 million new cases of brain metastases annually [3] - The non-invasive tumor radiation treatment market is projected to grow from RMB 27.2 billion in 2018 to RMB 59.4 billion by 2024, with a compound annual growth rate (CAGR) of 13.9% [3] 3. AI in Pathology - The NMPA's new guidelines for pathology services include AI-assisted diagnostics as an expansion item, which will help streamline the commercialization of AI technologies in pathology [5] 4. Innovative Drug Exports - The report notes that partnerships between Chinese companies and international firms are increasing, providing funding and reducing competition in the domestic market [6] - The innovative drug index has risen by 38.11% since the beginning of 2025, outperforming the CSI 300 index [6] 5. Oral Autoimmune Drugs - Takeda's new oral TYK2 inhibitor has shown positive results in clinical trials for psoriasis, indicating a potential breakthrough in treatment options [7] - Several domestic companies are also advancing in the development of oral autoimmune drugs targeting various conditions [7] 6. Small Nucleic Acid Drugs - Yuyuan Pharmaceutical's YKYY032 injection has received clinical approval from both the FDA and NMPA, with multiple companies in China advancing in the small nucleic acid drug space [9] - The report highlights the reliability of domestic technology platforms as they progress through clinical trials [9] 7. Stock Recommendations - The report recommends specific companies based on the identified opportunities, including Meihua Medical for BCI technology, Baiyang Pharmaceutical for ZAP-X, and Yuyuan Pharmaceutical for small nucleic acid drugs [11]

Group 1 - The core viewpoint of the news is that Yahuang Pharmaceutical has shown significant trading activity and financial performance, with a notable increase in revenue and a high level of financing and margin trading [1][2]. Group 2 - As of December 24, Yahuang Pharmaceutical's stock price decreased by 0.27%, with a trading volume of 60.89 million yuan [1]. - The financing buy-in amount on December 24 was 8.21 million yuan, while the financing repayment was 6.93 million yuan, resulting in a net financing buy of 1.28 million yuan [1]. - The total margin trading balance for Yahuang Pharmaceutical reached 211 million yuan, accounting for 4.40% of its market capitalization, indicating a high level of financing activity [1]. - The company has a high margin balance, with the margin balance exceeding the 70th percentile of the past year [1]. - On the same day, Yahuang Pharmaceutical repaid 2,200 shares in margin trading and sold 400 shares, with the selling amount calculated at 4,404 yuan [1]. - The margin balance of 30,020 yuan is above the 90th percentile of the past year, indicating a high level of short selling [1]. Group 3 - As of September 30, the number of shareholders for Yahuang Pharmaceutical was 25,200, a decrease of 1.06% from the previous period [2]. - The average number of circulating shares per shareholder increased by 16.41% to 17,294 shares [2]. - For the period from January to September 2025, Yahuang Pharmaceutical achieved a revenue of 216 million yuan, representing a year-on-year growth of 55.74% [2]. - The net profit attributable to the parent company was -24.9 million yuan, showing a year-on-year increase of 8.08% [2]. - Among the top ten circulating shareholders, Penghua Medical Technology Stock A ranked seventh, holding 6.14 million shares, a decrease of 401,700 shares compared to the previous period [2].

12月23日，亚虹医药跌1.52%，成交额8891.79万元。两融数据显示，当日亚虹医药获融资买入额790.28 万元，融资偿还945.64万元，融资净买入-155.36万元。截至12月23日，亚虹医药融资融券余额合计2.10 亿元。 融资方面，亚虹医药当日融资买入790.28万元。当前融资余额2.10亿元，占流通市值的4.36%，融资余 额超过近一年70%分位水平，处于较高位。 机构持仓方面，截止2025年9月30日，亚虹医药十大流通股东中，鹏华医药科技股票A（001230）位居 第七大流通股东，持股614.24万股，相比上期减少40.17万股。 责任编辑：小浪快报 资料显示，江苏亚虹医药科技股份有限公司位于上海市浦东新区东育路221弄前滩世贸中心(三期)B栋 19F，成立日期2010年3月16日，上市日期2022年1月7日，公司主营业务涉及创新药物的研发、生产和 销售。主营业务收入构成为：抗肿瘤类产品96.34%，其他3.66%。 截至9月30日，亚虹医药股东户数2.52万，较上期减少1.06%；人均流通股17294股，较上期增加 16.41%。2025年1月-9月，亚虹医药实现营业收入2.16亿元，同比 ...